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ABSTRACT 28 
Coffee is one of the most widely consumed beverages, and some studies have suggested it 29 
may be related to cardiovascular disease (CVD), the leading cause of poor health in the 30 
world. This manuscript reviews the evidence on the effect of habitual coffee consumption on 31 
CVD incidence and mortality. The review is based mostly on observational studies and meta-32 
analyses of the literature. In healthy people, compared to not consuming coffee, habitual 33 
consumption of 3-5 cups of coffee per day is associated with a 15% reduction in the risk of 34 
CVD, and higher consumption has not been linked to elevated CVD risk. Moreover, in 35 
comparison with no coffee intake, usual consumption of 1-5 cups/day is associated with a 36 
lower risk of death. In people who have already suffered a CVD event, habitual consumption 37 
does not increase the risk of a recurrent CVD or death. However, hypertensive patients with 38 
uncontrolled blood pressure should avoid consuming large doses of caffeine. In persons with 39 
well-controlled blood pressure, coffee consumption is probably safe, but this hypothesis 40 
should be confirmed by further investigations. 41 
KEY Words: Coffee, cardiovascular disease, mortality, cohort studies, experimental studies,   42 
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We summarize the evidence on the effects of habitual coffee consumption on cardiovascular 43 
disease (CVD) incidence and mortality. This topic is important because coffee is one of the 44 
most widely consumed beverages that has been shown to be modulate the risk of non-45 
communicable diseases1 and because CVD is the leading cause of poor health in the world. In 46 
2015 CVD accounted for 32% of all deaths and 14% of disability-adjusted life years (sum of 47 
the years of life lost due to premature mortality and the years lost due to disability).2   48 
We begin with a description of the composition of coffee, to understand plausible biological 49 
mechanisms derived from its components. Next we present an overview of the designs of 50 
studies on the effects of coffee on CVD, which helps to understand their strengths and 51 
limitations; we also focus on the main characteristics of coffee consumers among 52 
participants in large epidemiologic investigations because some characteristics may 53 
confound the relationship between coffee consumption and CVD, and thus should be 54 
controlled for in the analyses. Then, we describe the natural history of CVD, because it 55 
serves to identify the potential targets of coffee on CVD. The core of this article is a summary 56 
of the evidence on the effect of coffee on CVD and its risk factors. We end with some 57 
conclusions and a brief research agenda to further increase knowledge on the relationship 58 
between coffee and CVD.  59 
For the review of the effect of coffee on CVD and its risk factors we searched PubMed 60 
between 1 January 2010 and 31 August 2017; the search terms were “coffee,” “caffeine,” 61 
“cardiovascular disease” “cholesterol”, “blood pressure”, “review” and “meta-analysis”. We 62 
considered only studies in English or Spanish conducted with humans. We did not focus on 63 
individuals investigations, but we have outlined a few of them because they were large 64 
studies and seminal articles that have influenced research in the field, or may have 65 
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substantially contributed to pooled results in meta-analyses. The final reference list also 66 
includes articles retrieved from the identified reviews and was generated because of their 67 
relevance to the focus of this paper. 68 
Coffee composition 69 
Coffee has a very complex chemical composition, which includes caffeine, phenolic 70 
compounds, diterpenes, magnesium, trigonelline, quinides and lignans, among many others 71 
TOC graphic).3 The relative proportions of these compounds vary with the type of coffee 72 
bean, degree of roasting, and method of filtration. It is known that caffeine intake stimulates 73 
the release of adrenaline, producing multiple effects on the cardiovascular system such as 74 
increase blood pressure and heart rate, endothelial dysfunction, and reduced insulin 75 
sensitivity.4,5 These effects are consistent with the increased risk of suffering a coronary 76 
event or a stroke in the hours following coffee consumption.6,7 Nevertheless, studies in 77 
humans and animal models have yielded controversial results about the health effects of 78 
caffeine, which can be explained by population, type and dose of caffeine and low statistical 79 
power.8 80 
By contrast, other components in coffee, such as phenolic compounds (specially chlorogenic 81 
acid) magnesium, trigonelline and others, have been found to improve glucose and lipid 82 
metabolism, and to exert an antioxidant activity that reduces chronic inflammation and 83 
oxidative stress in the atherosclerotic process.9 Thus, it is plausible that the potentially 84 
harmful acute effects of caffeine could be offset by the beneficial effects of these other 85 
components in habitual drinkers, who have already developed caffeine tolerance.9 86 
Accordingly, habitual intake of total caffeine, regular coffee or decaffeinated coffee are not 87 
associated with higher risk of sudden cardiac death.10  88 
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Main study designs on the CVD effects of coffee 89 
The effect of coffee on biological risk factors of CVD is usually assessed with clinical trials, 90 
which are experimental studies where individuals are assigned (in most cases, randomly) to 91 
coffee or caffeine intake versus no intake. Their main advantage is appropriate control of 92 
extraneous variables, so that trials can provide sufficient evidence of the effect of coffee. 93 
Unfortunately, these studies have short duration and, thus, may not represent habitual 94 
coffee consumption. By contrast, long-term effects of habitual coffee intake are mostly 95 
examined with observational studies (e.g., prospective cohort studies) which have a large 96 
sample size and continued follow-up. Their main limitations are that they cannot totally 97 
exclude reverse causation (e.g., subclinical disease or poor health status leading to change in 98 
coffee intake, rather than the contrary) and residual confounding. This is the case where 99 
some variables mix their effect with that of coffee. A good example is confounding by 100 
tobacco smoking in investigations that have found an increased risk of cancer associated 101 
with heavy coffee intake; this resulted from the fact that smoking is a very strong cause of 102 
cancer and is correlated with coffee consumption, so the individual effects of tobacco and 103 
coffee may not be easily separated in data analyses.   104 
In practice, establishing a causal effect of coffee on CVD requires consistent evidence from 105 
clinical trials on cardiovascular risk factors and from observational studies on CVD events, as 106 
well as certain biological plausibility: compounds in coffee should show biological effects 107 
compatible with the purported effect of coffee on CVD (see next section).9 Lastly, the dose-108 
response relationship between coffee and CVD should be assessed, because the effect of 109 
coffee could vary across levels of consumption, as well as its risk-benefit ratio. This 110 
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information is crucial to elaborate coffee consumption guidelines addressed to the general 111 
population or to specific subgroups.  112 
Characteristics of coffee drinkers could confound the association between coffee and CVD. 113 
Compared to non-coffee drinkers, those with heavier intake of coffee have shown worse 114 
health behaviors. For instance, in some studies coffee drinkers have a higher frequency of 115 
smoking, greater alcohol intake and worse diet, and they do less physical activity.11,12 Also, 116 
some studies have shown that coffee drinkers have lower educational level and higher body 117 
weight than non-drinkers.12 Thus, statistical analyses in observational studies should attempt 118 
to separate the health effects of these variables from those of coffee. This is particularly 119 
important for coffee and smoking.  Given the strong correlation between coffee and tobacco 120 
smoking, and the fact that tobacco smoking is a potent CVD risk factor, multivariate 121 
adjustment may not suffice; thus, a better assessment of the effects of coffee may require 122 
restricting the analyses to never smokers.13 123 
Natural history of cardiovascular disease 124 
This comprises the sequence of events that begins with the initial exposure to the main CVD 125 
risk factors, which triggers the disease process, continues with the occurrence and diagnosis 126 
of CVD, and ends with its resolution as total recovery, sequelae (e.g., disability), or death 127 
(Figure 1).14 Among CVD risk factors, the most important are genetic and epigenetic factors, 128 
family history of premature disease, environmental contaminants (e.g., atmospheric 129 
pollution, noise), and health behaviors, such as tobacco smoking, physical activity, 130 
sedentariness and diet, which includes both food and beverage intake (e.g., coffee). If these 131 
risk factors remain elevated during a sufficient time, atherosclerosis develops and is 132 
frequently accompanied by alterations in biological risk factors, including body weight, blood 133 
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pressure, lipidemia, serum glucose, endothelial dysfunction, inflammation and thrombosis, 134 
among others.14 Moreover, a substantial fraction of individuals with continuous alteration of 135 
these biological factors may subsequently suffer an acute CVD event, such as myocardial 136 
infarction or stroke. Some of these events lead to death in a few hours or months but, 137 
among survivors, chronic forms of CVD disease (e.g. chronic heart failure) and disability 138 
could develop; these individuals may, in turn, suffer recurrent episodes of CVD (Figure 1).  139 
Accordingly, this review examines the associations between coffee and: 1) biological CVD 140 
risk factors; 2) atherosclerosis; 3) acute CVD events; 4) all-cause death; and 5) recurrent CVD 141 
events (Figure 1). 142 
Cardiovascular effects of coffee consumption 143 
1. Effects of coffee on biological risk factors of cardiovascular disease 144 
As regards habitual coffee consumption and blood lipids, a meta-analysis of 12 trials with 145 
1017 individuals aged 26-49 years followed during a mean of 45 days, found that coffee 146 
intake was associated with an average increase of 8.1 mg/dl for total cholesterol (TC), 5.4 147 
mg/dl for low-density lipoprotein cholesterol (LDL-C) and 12.6 mg/dl for triglycerides (TG).15 148 
The increase in TC was greater in trials using unfiltered coffee and regular coffee; also those 149 
who had hyperlipidemia were more sensitive to the cholesterol-raising effect of coffee. 150 
Moreover, meta-regression analyses revealed a positive dose-response relationship between 151 
coffee intake and TC, LDL-C and TG.15 Of note is that coffee diterpenes, cafestol and kahweol 152 
are the primary hypercholesterolemic agents in boiled coffee, and that their removal by 153 
filters significantly reduces the lipid-raising effect of coffee.16,17 Recent evidence indicates 154 
that coffee, which is low in diterpenes and caffeine, does not alter the blood lipid profile.18 155 
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Also of note is that instant coffee does not have cafestol and kawheol. Finally, more research 156 
in needed on the lipemic effect of espresso coffee. 157 
As for blood pressure (BP), a meta-analysis of 10 trials with people aged 25-73 years, 158 
followed during a mean of 60 days (enough to have developed tolerance), found no 159 
differences in BP by consumption of total, regular or decaffeinated coffee, but there was 160 
substantial heterogeneity across studies.19 It is not clear why the pressor effects of caffeine 161 
may be attenuated when administered via coffee, but it has been suggested that 162 
polyphenols favorably regulate BP, compensating for the effects of caffeine. Moreover, a 163 
dose-response meta-analysis of 7 cohorts, including 205,349 individuals and 44,120 cases of 164 
hypertension, found a 1% decreased risk of hypertension for each additional cup of coffee 165 
per day. Among subgroups, there were significant inverse associations for females, 166 
caffeinated coffee, and studies conducted in the US with longer follow-up. However, 167 
smoking-related variables weakened the strength of association between coffee 168 
consumption and risk of hypertension.20 Thus, there is no epidemiological evidence of a 169 
detrimental effect of coffee on hypertension risk. 170 
Among hypertensive patients, a review of 5 trials showed that the administration of 200-300 171 
mg caffeine produced a mean increase of 8.1 mm Hg in systolic BP and of 5.7 mm Hg in 172 
diastolic BP. The increase in BP was observed in the first hour after caffeine intake and lasted 173 
3 h. Additionally, in 3 studies of the longer-term effect (2 weeks) of regular coffee 174 
consumption, no increase in BP was observed when it was compared with a caffeine-free 175 
diet or with decaffeinated coffee.21 However in a recent cross-sectional study of 176 
hypertensive older patients, we found that habitual coffee consumption of ≥3 cups/day was 177 
associated with uncontrolled BP, as evidenced from 24-h ambulatory BP monitoring.22 178 
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Therefore, it is prudent that physicians and other health professionals ask hypertensive 179 
patients, in particular those with uncontrolled BP, about habitual coffee consumption; and 180 
moderating coffee intake may be a simple strategy to maintain or improve BP control among 181 
the elderly. 182 
The metabolic syndrome (MS) is a cluster of biological factors, including abdominal obesity, 183 
dyslipidemia, high blood pressure and elevated serum glucose, which behaves as an 184 
important risk factor for diabetes and CVD. A meta-analysis of 8 studies, published up to 185 
March 2015, reported that individuals with the highest coffee consumption were 13% less 186 
likely to have the MS. However, there was substantial heterogeneity in results between 187 
studies; also, the association of coffee and individual components of MS was not consistent 188 
across the studies.23 There is some evidence that that favorable metabolic effects of 189 
caffeine-containing coffee may partly operate through associations with serum 190 
concentrations of adiponectin. A protein hormone secreted from adipose tissue that 191 
modulates several metabolic processes, including glucose regulation and fatty acid 192 
oxidation. Specifically, in women from the Nurses’ Health Study, habitual consumption of ≥4 193 
cups/day of caffeine-containing coffee has been associated with 20% higher serum 194 
adiponectin concentrations than those associated with habitual consumption of <4 cups of 195 
coffee daily;24 this indicates that increased adiponectin may play a role in the beneficial 196 
effects of coffee on insulin sensitivity (an underlying mechanisms of the MS). 197 
Coffee is the main source of polyphenols in the diet of European populations, and it 198 
accounts for up to 40% of polyphenol intake, mostly in the form of chlorogenic, ferulic, and 199 
p-coumaric acids.25,26,27 Given that these compounds reduce oxidative stress and chronic 200 
inflammation, and that these processes play a key role in the pathogenesis of 201 
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atherosclerosis, this could be a biological pathway for the association between coffee and 202 
CVD.28 In a seminal work in the Nurses’ Health Study I cohort, no appreciable differences in 203 
plasma concentrations of markers of inflammation and endothelial function were found 204 
across categories of regular coffee intake in healthy women. In those with type 2 diabetes, 205 
higher regular and decaffeinated coffee consumption were associated with lower plasma 206 
concentrations of E-selectin and C-reactive protein.29 Unfortunately, other observational 207 
studies30-33 and clinical trials34-35 on the effect of coffee on inflammatory markers, such as C-208 
reactive protein and Interleukin-6, have yielded inconsistent results (direct, inverse, and no 209 
associations were reported).  210 
2. Coffee consumption and atherosclerosis 211 
Several studies have found inconsistent results on the association between coffee 212 
consumption and coronary artery calcium, which is a marker of coronary atherosclerosis; 213 
specifically, two cross-sectional studies reported a protective effect of coffee on 214 
atherosclerosis36,37 while two longitudinal studies found no association.38,39 The Rotterdam 215 
Coronary Calcification Study reported an inverse association between coffee consumption 216 
and coronary calcification in women, but not in men,36 and in the Kangbuk Samsung Health 217 
Study moderate coffee consumption was associated with a lower prevalence of subclinical 218 
coronary atherosclerosis.37 By contrast, in the CARDIA study no substantial association was 219 
observed between coffee or caffeine intake and coronary and carotid atherosclerosis,38 and 220 
in the MESA study regular coffee intake was not statistically linked to coronary artery 221 
calcium progression; however, caffeine intake was marginally inversely associated with 222 
coronary artery calcium progression.39  223 
3. Coffee consumption and cardiovascular disease events 224 
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During 14 years of follow-up among men participating in the Health Professionals Follow-up 225 
study, regular coffee consumption of up to 6 cups/day was not associated with a higher risk 226 
of total, fatal or non-fatal coronary heart disease (CHD). Also, habitual consumption of 227 
decaffeinated coffee or tea, and caffeine intake, were not linked to CHD risk. Moreover, in 228 
this large study, coffee consumption was not associated with higher levels of blood lipids.40 229 
Similar results were obtained during a 20-year follow-up of women in the Nurses’ Health 230 
Study.40  231 
As regards stroke, results from women followed during 24 years in the Nurses’ Health Study 232 
showed that habitually consuming either 2-3 or 4 cups of coffee per day was  associated with 233 
a 20% lower risk; these results applied to both ischemic and hemorrhagic stroke. The 234 
association was stronger among never and past smokers than among current smokers. Other 235 
drinks containing caffeine such as tea and caffeinated soft drinks were not associated with 236 
stroke. Finally, decaffeinated coffee showed a trend toward lower risk of stroke after 237 
adjustment for consumption of regular coffee.41  238 
The above-mentioned investigations were also included in a recent meta-analysis of 36 239 
studies, with 1.2 million participants and 36,352 CVD events. The main finding was a 240 
nonlinear association between coffee and CVD risk; compared to non-coffee drinkers, the 241 
risk of total CVD, of CHD and of stroke was 10-15% lower in moderate drinkers (3-5 cups of 242 
coffee/day). Higher consumption of coffee was not associated with elevated CVD disease 243 
risk.42 Results were robust in stratified analyses according to disease endpoints, geographic 244 
locations of the studies, type of coffee, and baseline characteristics of the study populations. 245 
However, most of the participants’ coffee consumption in the reviewed studies was 246 
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probably in the form of filtered coffee; thus, the results may not apply to unfiltered coffee 247 
(e.g., French press, Scandinavian boiled, or Turkish/Greek coffee).42 248 
The authors of the aforementioned study argued that the nonlinear U-shaped relationship 249 
between coffee consumption and risk of CVD might be due to a combination of beneficial 250 
and detrimental effects.42 As commented above, coffee may improve glucose metabolism 251 
and reduce inflammation and LDL-oxidation. However, caffeine in coffee may produce short-252 
term elevation of BP and reduce BP control in hypertensive patients. It is possible that the 253 
beneficial effects are greater than the adverse effects for moderate coffee consumption, 254 
whereas for heavy consumption the detrimental effects may counterbalance beneficial 255 
effects.   256 
Heart failure is one of the CVD epidemics of the XXI century. Mostofsky et al. have reviewed 257 
5 independent prospective studies of coffee consumption and heart failure risk, including 258 
6522 heart failure events and 140,220 participants.43 They found a statistically significant J-259 
shaped relationship between coffee and heart failure. Compared with no consumption, the 260 
strongest inverse association was seen for 4 cups/day and a potentially higher risk at higher 261 
levels of consumption. Results were not modified by sex or by baseline history of myocardial 262 
infarction or diabetes.43 The inverse association between coffee and heart failure is 263 
somewhat expected because CHD is one of the main causes of heart failure and, as 264 
commented above, moderate coffee intake has also shown an inverse association with CHD.  265 
Lastly, since coffee intake produces a short-term increase in BP, it is of interest to assess the 266 
impact of coffee and CVD in hypertensive patients. A systematic review of 7 cohort studies 267 
found no evidence of an association between habitual coffee consumption and a higher risk 268 
of CVD in these patients.21 269 
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4. Coffee consumption and all-cause mortality 270 
Among 41,736 men and 86,214 women with no history of CVD or cancer at baseline who 271 
were followed during 18 years and 24 years, respectively, we found in a previous study an 272 
inverse association between habitual coffee consumption and all-cause death.44 This 273 
association, which was more evident in women than men, was mainly due to a moderately 274 
reduced risk for CVD mortality and was independent of caffeine intake. Coffee consumption 275 
was not linked to risk for cancer death after adjustment for potential confounders. Lastly, 276 
decaffeinated coffee consumption was associated with a small reduction in all-cause and 277 
CVD mortality.44 278 
A subsequent large analysis of the National Institutes of Health-AARP Diet and Health Study, 279 
which included 229,119 men and 173,141 women aged 50-71 years and free of CVD and 280 
cancer at baseline, found a significant inverse association between coffee consumption and 281 
mortality.45 The lowest risk was observed for those consuming 4-5 cups/day. Inverse 282 
associations were observed for deaths due to heart disease, respiratory disease, stroke, 283 
injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results 284 
were similar in subgroups, including persons who had never smoked and persons who 285 
reported very good-to-excellent health at baseline.45 286 
Several subsequent meta-analyses of the literature46-48 and pooling of individual data49 have 287 
assessed the association between coffee and all-cause death. They reported a modest non-288 
linear inverse association, which probably applies to both regular and decaffeinated coffee.  289 
The most recent meta-analysis has included 31 studies comprising 1,610,543 individuals with 290 
183,991 cases of all-cause, 34,574 of CVD, and 40,991 of cancer deaths.13 Analyses showed 291 
decreased all-cause and CVD mortality associated with coffee consumption in both smokers 292 
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and non-smokers. Among non-smokers, an increase of 1 cup/day of coffee yielded a linear 293 
decreased risk of death from all-causes (relative risk [RR] = 0.94) and from CVD (RR = 0.94). 294 
However, smoking modified the association between coffee and cancer. Whereas in 295 
smokers, the risk of cancer increased progressively with coffee consumption, non-smokers 296 
showed an inverse continuous association (RR = 0.98 per cup/day). The direct association 297 
between coffee intake and cancer risk in smokers was interpreted as a manifestation of 298 
confounding by smoking, whereby the protective effect of coffee was attenuated by the 299 
increased risk of cancer due to smoking.13  300 
The EPIC and MEC studies have examined the association between coffee and mortality 301 
across countries and ethnic groups. The EPIC study, a large cohort of over 500.000 302 
individuals from 10 European countries with an average follow-up of 16 years, found an 303 
inverse relationship between coffee intake and all-cause or CVD mortality in men and 304 
women.50 The findings were consistent across countries, which increases their 305 
generalizability because populations used different coffee preparation methods and had 306 
different drinking patterns. The MEC study followed more than 185 000 African Americans, 307 
Native Hawaiians, Japanese Americans, Latinos, and whites for an average of 16 years and 308 
also found a lower all-cause or CVD mortality associated with coffee drinking in all 309 
racial/ethnic groups.51 This study substantially increases the generalizability of previous 310 
findings across the racial/ethnic spectrum. 311 
Mendelian randomization studies have attempted to shed some light on whether the 312 
association between coffee and mortality is causal or not. While these investigations have 313 
confirmed that, observationally, coffee intake was associated with U-shaped lower CVD 314 
disease and all-cause mortality, genetically, caffeine intake was not associated with risk of 315 
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CVD or all-cause death.52 Moreover, given that alleles representing intake of caffeine are 316 
associated with greater coffee consumption, that coffee is the main source of caffeine, and 317 
that results were similar after excluding tea and cola drinkers, these analyses do not support 318 
the hypothesis that the association is causal. However, they do not entirely negate the 319 
hypothesis because the genetic associations with coffee intake in this study were relatively 320 
small compared with observational differences in coffee intake and, thus, it had limited 321 
statistical power to rule out a causal association between coffee and mortality.52 Additional 322 
research is clearly needed to establish causation in the association between coffee and 323 
mortality. 324 
5. Coffee consumption and recurrent CVD and mortality in individuals who already 325 
suffered a CVD 326 
The few studies conducted on patients with CVD have yielded somewhat inconsistent 327 
results. In a population-based case-control study, heavy coffee consumption was associated 328 
with higher risk of sudden cardiac death.53 Another study, in patients hospitalized for acute 329 
myocardial infarction, found a strongly protective association between heavy coffee 330 
consumption and all-cause mortality after 90 days of follow-up, but not after 4 years of 331 
follow-up.54 Also, cumulative consumption of nonfiltered coffee was not associated with the 332 
risk of a second CVD event in another 3-year follow-up study.55 By contrast, filtered coffee 333 
consumption during the year preceding the coronary event has been linked to lower all-334 
cause mortality in a 10-year prospective study of survivors of an acute myocardial 335 
infarction.56 Finally, we examined the association between filtered caffeinated coffee 336 
consumption and the risk of all-cause and CVD death in 11,697 women with CVD followed 337 
during 24 years in the Nurses’ Health Study. The main advantages of this study were the long 338 
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follow-up, the large size of the cohort, and the fact that coffee intake was assessed both 339 
before and after the CVD event every 4 years. We did not find an association between long-340 
term filtered caffeinated coffee consumption and risk of all-cause or CVD death. Neither was 341 
shorter-term coffee consumption associated with mortality in these women.57 Thus, with the 342 
exception of one case-control study, whose small sample size and retrospective design may 343 
limit the validity of the results, the available evidence suggests that in survivors of a CVD, 344 
coffee intake does not increase, and might even lower, the risk of a recurrent CVD event or 345 
death.58 346 
We conclude that, in healthy people, habitual consumption of 3-5 cups of coffee/day is 347 
associated with a 15% reduction in the risk of CVD, and higher consumption has not been 348 
linked to elevated CVD risk. Also, usual intake of 1-5 cups/day is associated with lower risk of 349 
all-cause mortality. Finally, in people who have already suffered a CVD event, habitual 350 
consumption does not increase the risk of a recurrent CVD or death. Thus, moderate coffee 351 
intake can be part of a healthy diet for most people.59 352 
However, among hypertensive patients, those with uncontrolled BP should avoid consuming 353 
large doses of caffeine. In those with well-controlled BP, coffee consumption is probably 354 
safe, but this hypothesis should be confirmed by further investigations. 355 
Despite the substantial amount of evidence indicating that coffee consumption is safe, and 356 
even beneficial for cardiovascular health, if physicians are to offer sound medical advice on 357 
this subject, more research will be required in the following areas: 358 
a) Better characterization of the effect of coffee in high risk populations, specifically,  359 
hypertensive patients with poorly controlled BP and patients with heart failure with and 360 
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without atrial fibrillation; this is a frequent comorbidity in heart failure, whose risk could 361 
be modified by caffeine.60-62 362 
b) Given that most studies have been performed on filtered regular coffee, more research 363 
is needed on other types of coffee preparation (boiled-unfiltered, espresso, instant) and 364 
on decaffeinated coffee, though it seems that the associated CVD risk is similar to that 365 
for regular coffee. 366 
c) The effect of coffee on patient-reported outcomes (e.g., quality of life in the general 367 
population or in patients with CHD or heart failure).63 368 
d) The effect of genetic polymorphisms, particularly of the cytochrome P450 1A2 (CYP1A2) 369 
enzyme, on the pharmacokinetics and pharmacodynamics of caffeine, because those 370 
polymorphisms can contribute to can explain inter-individual variability in the amount of 371 
coffee consumed64 as well as in their health effects.65,66  372 
 373 
 374 
  375 
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Figure 1. Natural history of cardiovascular disease, including the potential targets for the effect of coffee consumption.  
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